Lisavanbulin Uses, Dosage, Side Effects and more
Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Trade Name | Lisavanbulin |
Generic | Lisavanbulin |
Lisavanbulin Other Names | Lisavanbulin |
Type | |
Formula | C26H29N9O3 |
Weight | Average: 515.578 Monoisotopic: 515.23933583 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |